RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Clivel Charlton to Antiparkinson Agents

This is a "connection" page, showing publications Clivel Charlton has written about Antiparkinson Agents.
Connection Strength

1.188
  1. Smith ML, King J, Dent L, Mackey V, Muthian G, Griffin B, Charlton CG. Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease. Life Sci. 2014 Aug 06; 110(1):1-7.
    View in: PubMed
    Score: 0.485
  2. King JM, Muthian G, Mackey V, Smith M, Charlton C. L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease. Life Sci. 2011 Oct 24; 89(17-18):638-43.
    View in: PubMed
    Score: 0.400
  3. Lee ES, Chen H, King J, Charlton C. The role of 3-O-methyldopa in the side effects of L-dopa. Neurochem Res. 2008 Mar; 33(3):401-11.
    View in: PubMed
    Score: 0.303
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support